In addition, we subdivided the cancer samples into two groups: (i) tumors that had known clinically relevant mutations in EGFR signaling genes: EGFR, KRAS, NRAS, and BRAF, and (ii) “wild type” tumors that did not have these mutations. Here, KRAS is linked to cancer.